


## SNC80

<b>Cat. No.:</b>	HY-101202
<b>CAS No.:</b>	156727-74-1
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>39</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	449.63
<b>Target:</b>	Opioid Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SNC80 (NIH 10815) is a potent, highly selective and non-peptide $\delta$ -opioid receptor agonist with a $K_i$ of 1.78 nM and an $IC_{50}$ of 2.73 nM. SNC80 also selectively activates $\mu$ - $\delta$ heteromer in HEK293 cells with an $EC_{50}$ of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant-like effects. SNC80 has the potential for multiple headache disorders treatment <sup>[1][2][3][4][5][6]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 2.73 nM ( $\delta$ -opioid receptor), 5457 nM ( $\mu$ -opioid receptor) <sup>[3]</sup> Ki: 1.78 nM ( $\delta$ -opioid receptor), 881.5 nM ( $\mu$ -opioid receptor) and 441.8 nM ( $\kappa$ -opioid receptor) <sup>[2]</sup>								
<b>In Vitro</b>	SNC80 selectively activates $\mu$ - $\delta$ heteromer in HEK293 cells with an $EC_{50}$ of 52.8 nM. SNC80 exhibits substantially greater activity in cells coexpressing $\mu$ - and $\delta$ -opioid receptors than in cells either singly expressing $\delta$ -opioid receptors or coexpressing $\delta$ - and $\kappa$ -opioid receptors <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	SNC80 (10 mg/kg; intraperitoneal injection; once; C57BL6/J mice) treatment significantly attenuated this allodynia caused by overuse of Sumatriptan <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male and female C57BL6/J mice (20-30g) injected with Sumatriptan<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; once</td> </tr> <tr> <td>Result:</td> <td>Significantly attenuated allodynia.</td> </tr> </table>	Animal Model:	Male and female C57BL6/J mice (20-30g) injected with Sumatriptan <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection; once	Result:	Significantly attenuated allodynia.
Animal Model:	Male and female C57BL6/J mice (20-30g) injected with Sumatriptan <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	Intraperitoneal injection; once								
Result:	Significantly attenuated allodynia.								

### REFERENCES

[1]. Moyer LS, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. *Neuropharmacology*. 2019 Apr;148:77-86.

[2]. Bilsky EJ, et al. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. *J Pharmacol Exp Ther*. 1995 Apr;273(1):359-66.

[3]. Calderon SN, et al. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. *J Med Chem*. 1994 Jul 8;37(14):2125-8.

---

[4]. Vicente-Sanchez A, et al. The delta opioid receptor tool box. *Neuroscience*. 2016 Dec 3;338:145-159.

[5]. Dripps IJ, et al. Role of signalling molecules in behaviours mediated by the  $\delta$  opioid receptor agonist SNC80. *Br J Pharmacol*. 2018 Mar;175(6):891-901.

[6]. Metcalf MD, et al. The  $\delta$  opioid receptor agonist SNC80 selectively activates heteromeric  $\mu$ - $\delta$  opioid receptors. *ACS Chem Neurosci*. 2012 Jul 18;3(7):505-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA